Online citations, reference lists, and bibliographies.
← Back to Search

Nano-Biomaterials For Ophthalmic Drug Delivery

Y. Pathak, V. Sutariya, A. Hirani
Published 2016 · Chemistry

Cite This
Download PDF
Analyze on Scholarcy
Share
The capabilities of nanotechnology are leading to widespread use of nanomaterials in biotechnology and medicine. Nanomaterials exist in various sizes, compositions, and morphology. Due to their large numbers, classifi cation systems should be implemented for proper evaluation of the nanomaterials for effi cacy and prevention of toxicity. Many nanomaterials are being studied for potential therapeutic applications in ocular disease. Conventional treatments still possess side effects and limitations and the use of nano-biomaterials for ophthalmic drug delivery can allow for design and administration of delivery systems with targeted and sustained release capabilities. Additionally, off-target activities and toxicity can be reduced.
This paper references
10.1016/J.IJANTIMICAG.2005.07.012
Inhalable alginate nanoparticles as antitubercular drug carriers against experimental tuberculosis.
Zahoor Ahmad (2005)
10.1167/iovs.07-1077
Novel hyaluronic acid-chitosan nanoparticles for ocular gene therapy.
M. de la Fuente (2008)
Nanoparticle based DPI formulation for active targeting of etoposide in lung cancer
A Shrivastava (2012)
10.1016/B978-044451967-2/00146-X
2.19 – Storage Plant Polysaccharides: Xyloglucans, Galactomannans, Glucomannans
K. Nishinari (2007)
10.1016/S0168-3659(97)00172-7
An AB block copolymer of oligo(methyl methacrylate) and poly(acrylic acid) for micellar delivery of hydrophobic drugs.
T. Inoué (1998)
10.1016/S0169-409X(02)00044-3
Nanoparticles in cancer therapy and diagnosis.
I. Brigger (2002)
Aspirin Loaded Albumin Nanoparticles by Coacervation: Implications in Drug Delivery
Saikat Das (2005)
10.1073/PNAS.88.14.6224
CD62 and endothelial cell-leukocyte adhesion molecule 1 (ELAM-1) recognize the same carbohydrate ligand, sialyl-Lewis x.
M. Polley (1991)
10.1201/9780849374555.CH11
Nanoparticles for Ocular Drug Delivery
A. Amrite (2006)
Biomaterials in ophthalmic drug delivery
M. Sintzel (1996)
10.3109/10717544.2011.589088
In vitro release characteristics and cellular uptake of poly(D,L-lactic-co-glycolic acid) nanoparticles for topical delivery of antisense oligodeoxynucleotides
Ying-Shan Chen (2011)
10.1016/0168-3659(93)90097-O
Preparations of biodegradable nanospheres of water-soluble and insoluble drugs with D, L-lactide/glycolide copolymer by a novel spontaneous emulsification solvent diffusion method, and the drug release behavior.
Toshiyuki (1993)
10.1016/S0142-9612(02)00080-7
Flurbiprofen-loaded acrylate polymer nanosuspensions for ophthalmic application.
R. Pignatello (2002)
10.5301/EJO.2010.6051
Drug Delivery to the Posterior Segment of the Eye
N. Fischer (2011)
Nanoparticulate in-situ gels of TPGS, gellan and PVA as vitreous humor substitutes
R Banerjee (2013)
10.4103/0975-7406.111824
Nanoparticles laden in situ gel for sustained ocular drug delivery
H. Gupta (2013)
10.1089/jop.2010.0158
Comparison of long-acting bevacizumab formulations in the treatment of choroidal neovascularization in a rat model.
C. K. Pan (2011)
10.1007/s00396-012-2854-0
Novel pentablock copolymer (PLA–PCL–PEG–PCL–PLA)-based nanoparticles for controlled drug delivery: effect of copolymer compositions on the crystallinity of copolymers and in vitro drug release profile from nanoparticles
Viral Tamboli (2012)
10.1021/NL051679D
Nanotechnology-based photodynamic therapy for neovascular disease using a supramolecular nanocarrier loaded with a dendritic photosensitizer.
Ryuichi Ideta (2005)
10.1016/0378-5173(86)90236-X
Development of a new process for the manufacture of polyisobutylcyanoacrylate nanocapsules
N. A. K. Fallouh (1986)
10.3109/03639048609048026
Interfacial Polymerization, A Useful Method for the Preparation of Polymethylcyanoacrylate Nanoparticles
H. Krause (1986)
10.1089/jop.2010.0048
In vitro evaluation of a targeted and sustained release system for retinoblastoma cells using Doxorubicin as a model drug.
S. H. S. Boddu (2010)
10.1167/IOVS.05-0495
Chitosan nanoparticles as a potential drug delivery system for the ocular surface: toxicity, uptake mechanism and in vivo tolerance.
Amalia Enríquez de Salamanca (2006)
10.1016/j.jconrel.2014.06.043
Ocular delivery of macromolecules.
Y. C. Kim (2014)
10.1007/s10529-006-9219-z
Hyaluronic acid: a natural biopolymer with a broad range of biomedical and industrial applications
G. Kogan (2006)
10.3109/03639049709148498
Mucoadhesive Drug Delivery Systems
A. Ahuja (1997)
10.1002/JPS.20216
Cellular interactions and in vitro DNA transfection studies with poly(ethylene glycol)-modified gelatin nanoparticles.
Goldie Kaul (2005)
10.1023/A:1018936205485
Poly(ε-Caprolactone) Nanocapsules in Carteolol Ophthalmic Delivery
L. Marchal-Heussler (2004)
10.1016/S0928-0987(03)00178-7
The effect of a PEG versus a chitosan coating on the interaction of drug colloidal carriers with the ocular mucosa.
A. M. de Campos (2003)
10.1021/JS950474+
Comparative in vitro evaluation of several colloidal systems, nanoparticles, nanocapsules, and nanoemulsions, as ocular drug carriers.
P. Calvo (1996)
10.1167/iovs.10-5392
Ophthalmic drug delivery systems for the treatment of retinal diseases: basic research to clinical applications.
H. Edelhauser (2010)
10.1186/1746-1596-6-64
Target drug delivery system as a new scarring modulation after glaucoma filtration surgery
Tingting Shao (2011)
10.1016/S0378-5173(97)00255-X
Methylmethacrylate sulfopropylmethacrylate copolymer nanoparticles for drug delivery: Part III: Evaluation as drug delivery system for ophthalmic applications
K. Langer (1997)
10.1007/s11095-008-9756-3
Intrascleral Drug Delivery to the Eye Using Hollow Microneedles
J. Jiang (2008)
10.3109/03639049709148693
Influence of Irradiation Sterilization on Polymers Used as Drug Carriers—A Review
M. Sintzel (1997)
An ophthalmic drug delivery system
A. Chauhan (2003)
10.1016/0166-6622(88)80173-2
Spontaneous emulsification produced by diffusion. A review
C. Miller (1988)
10.1167/IOVS.06-1242
Prolonged protective effect of basic fibroblast growth factor-impregnated nanoparticles in royal college of surgeons rats.
T. Sakai (2007)
10.5681/bi.2011.003
Impacts of nanomedicines in ocular pharmacotherapy.
A. Nakhlband (2011)
10.1016/j.colsurfb.2009.09.001
Biodegradable polymeric nanoparticles based drug delivery systems.
A. Kumari (2010)
10.1016/j.preteyeres.2010.08.002
Applications of nanoparticles in ophthalmology
Y. Diebold (2010)
Cordia obliqua wild fruits
C Parmar (1982)
10.1016/J.CARBPOL.2006.01.020
Preparation of cholesterol-modified chitosan self-aggregated nanoparticles for delivery of drugs to ocular surface
X. Yuan (2006)
10.2174/18779123112029990004
Patent Review on Nanotechnology in Ocular Drug Delivery
N. Gupta (2013)
10.1007/s11095-008-9800-3
Methods for the Preparation and Manufacture of Polymeric Nanoparticles
C. Vauthier (2008)
10.2337/db08-1327
Nanoparticle-Mediated Expression of an Angiogenic Inhibitor Ameliorates Ischemia-Induced Retinal Neovascularization and Diabetes-Induced Retinal Vascular Leakage
K. Park (2009)
10.1016/J.IJPHARM.2004.01.033
Factorial design, physicochemical characterisation and activity of ciprofloxacin-PLGA nanoparticles.
K. Dillen (2004)
10.1016/S0168-3659(00)00339-4
Biodegradable polymeric nanoparticles as drug delivery devices.
K. Soppimath (2001)
10.1016/j.drudis.2007.10.021
Nanotechnology in ocular drug delivery.
S. Sahoo (2008)
10.1211/0022357023835
Eudragit RL100 nanoparticle system for the ophthalmic delivery of cloricromene
C. Bucolo (2004)
10.1016/J.CARBPOL.2010.03.065
Preparation and evaluation of nanoparticles of gum cordia, an anionic polysaccharide for ophthalmic delivery
Monika Yadav (2010)
10.1002/mabi.200700190
Novel hyaluronan-based nanocarriers for transmucosal delivery of macromolecules.
M. de la Fuente (2008)
10.1016/S0169-409X(00)00116-2
Nanoparticulate systems for the delivery of antisense oligonucleotides.
G. Lambert (2001)
10.1167/iovs.10-5676
Therapeutic effect of stealth-type polymeric nanoparticles with encapsulated betamethasone phosphate on experimental autoimmune uveoretinitis.
T. Sakai (2011)
10.1615/CRITREVTHERDRUGCARRIERSYST.V19.I2.10
Nanocapsule technology: a review.
P. Couvreur (2002)
Sparfl oxacin-loaded PLGA nanoparticles for sustained ocular drug delivery
H Gupta (2010)
10.1002/9781118015810.CH1
Biodegradable Polymers in Drug Delivery
J. Jain (2011)
10.1016/j.ijpharm.2014.03.042
A new combination approach of CI jet and QESD to formulate pH-susceptible amorphous solid dispersions.
S. Kumar (2014)
10.3109/1061186X.2010.504268
Biodegradable levofloxacin nanoparticles for sustained ocular drug delivery
H. Gupta (2011)
10.1016/j.ejps.2012.08.008
Chitosan coated sodium alginate-chitosan nanoparticles loaded with 5-FU for ocular delivery: in vitro characterization and in vivo study in rabbit eye.
R. C. Nagarwal (2012)
10.1002/JPS.20685
Flurbiprofen loaded biodegradable nanoparticles for ophtalmic administration.
E. Vega (2006)
10.1098/rsif.2009.0285.focus
Targeted drug-delivery approaches by nanoparticulate carriers in the therapy of inflammatory diseases
W. Ulbrich (2009)
10.1016/J.CARBPOL.2007.11.007
Chitosan nanoparticles loaded with dorzolamide and pramipexole
Sofia A. Papadimitriou (2008)
Method for the production of nanoparticles and microparticles by ternary agent concentration and temperature alteration induced immiscibility
A Raiche (2004)
Ophthalmic formulation of a selective cyclooxygenase-2 inhibitory drug
TT Kararli (2002)
10.1155/2013/238351
Cationic gelatin nanoparticles for drug delivery to the ocular surface: in vitro and in vivo evaluation
Ching Li Tseng (2013)
10.1002/1520-6017(200103)90:3<288::AID-JPS4>3.0.CO;2-5
Ocular tolerability and in vivo bioavailability of poly(ethylene glycol) (PEG)-coated polyethyl-2-cyanoacrylate nanosphere-encapsulated acyclovir.
M. Fresta (2001)
10.3109/10611860903450023
Hyaluronic acid modified chitosan nanoparticles for effective management of glaucoma: development, characterization, and evaluation
Sheetu Wadhwa (2010)
Sustained Release Intraocular Drug Delivery Devices for Treatment of Uveitis
N. Haghjou (2011)
10.1016/S0939-6411(03)00187-5
Preparation and evaluation of drug-loaded gelatin nanoparticles for topical ophthalmic use.
J. Vandervoort (2004)
10.1016/J.IJPHARM.2006.11.028
Encapsulation of dexamethasone into biodegradable polymeric nanoparticles.
Carolina Gómez-Gaete (2007)
10.1016/J.IJPHARM.2006.01.041
Evaluation of ciprofloxacin-loaded Eudragit RS100 or RL100/PLGA nanoparticles.
K. Dillen (2006)
10.1016/S0142-9612(01)00127-2
Preparation of controlled release ophthalmic drops, for glaucoma therapy using thermosensitive poly-N-isopropylacrylamide.
Ging-Ho Hsiue (2002)
10.2174/1877912311202020156
A Review on Patented Nanotechnology used for Ocular Drug Delivery
Swarnali Daspaul (2012)
10.1016/J.BIOMATERIALS.2006.11.028
Ocular drug delivery by liposome-chitosan nanoparticle complexes (LCS-NP).
Y. Diebold (2007)
10.1023/A:1012128907225
Chitosan and Chitosan/Ethylene Oxide-Propylene Oxide Block Copolymer Nanoparticles as Novel Carriers for Proteins and Vaccines
P. Calvo (2004)
10.1002/jps.21383
PLGA nanospheres for the ocular delivery of flurbiprofen: drug release and interactions.
E. Vega (2008)
10.1080/107175400455128
Pluronic F127-based ocular delivery system containing biodegradable polyisobutylcyanoacrylate nanocapsules of pilocarpine.
S. D. Desai (2000)
10.1016/0168-3659(94)90225-9
Evaluation of pilocarpine-loaded albumin particles as drug delivery systems for controlled delivery in the eye. I: In vitro and in vivo characterisation
A. Zimmer (1994)
Multi-functional biodegradable particles for selectable targeting, imaging, and therapeutic delivery and use thereof for treating ocular disorders
R Xu (2010)
10.1016/0378-5173(89)90167-1
The kinetics of in vitro release and the pharmacokinetics of miotic response in rabbits of gelatin and albumin microspheres with pilocarpine
Sorin E. Leucuţ¸a (1989)
10.1016/j.jconrel.2013.01.004
Specific uptake of folate-decorated triamcinolone-encapsulating nanoparticles by retinal pigment epithelium cells enhances and prolongs antiangiogenic activity.
Wai-Leung Langston Suen (2013)
10.1097/ICO.0b013e3181bd9eee
Ocular Tolerance to a Topical Formulation of Hyaluronic Acid and Chitosan-Based Nanoparticles
L. Contreras-Ruiz (2010)
10.1083/JCB.117.4.895
The three members of the selectin receptor family recognize a common carbohydrate epitope, the sialyl Lewis(x) oligosaccharide
C. Foxall (1992)
10.1080/02652040600612439
Polymorphic behaviour of Compritol®888 ATO as bulk lipid and as SLN and NLC
E. Souto (2006)
10.1007/s11095-006-9748-0
Oligonucleotide-Polyethylenimine Complexes Targeting Retinal Cells: Structural Analysis and Application to Anti-TGFβ-2 Therapy
A. L. Gomes dos Santos (2006)
10.1167/iovs.09-3914
Does a nanomolecule of Carboplatin injected periocularly help in attaining higher intravitreal concentrations?
Debraj Shome (2009)
10.1016/S0378-5173(01)00614-7
Prolonged hypoglycemic effect of insulin-loaded polybutylcyanoacrylate nanoparticles after pulmonary administration to normal rats.
Q. Zhang (2001)
Synthesis of thiolated chitosan and preparation nanoparticles with sodium alginate for ocular drug delivery
X. Zhu (2012)
10.4314/TJPR.V5I1.14634
Nanoparticles - A Review
V. Mohanraj (2007)
Investigation of the factors infl uencing the incorporation of clotrimazole in SLN and NLC prepared by hot high-pressure homogenization
E Souto (2006)
10.1021/mp200155t
Expression of MUC5AC in ocular surface epithelial cells using cationized gelatin nanoparticles.
Giovanni Konat Zorzi (2011)
Influence of sterilization processes on poly(epsilon-caprolactone) nanospheres.
V. Masson (1997)
10.1016/S0378-5173(01)00622-6
Combined hydroxypropyl-beta-cyclodextrin and poly(alkylcyanoacrylate) nanoparticles intended for oral administration of saquinavir.
H. Boudad (2001)
10.1023/B:PHAM.0000036917.75634.be
Physicochemical Parameters Associated with Nanoparticle Formation in the Salting-Out, Emulsification-Diffusion, and Nanoprecipitation Methods
S. Galindo-Rodriguez (2004)
10.1016/S0169-409X(01)00194-6
Novel ophthalmic therapeutic modalities based on noninvasive light-targeted drug delivery to the posterior pole of the eye.
R. Zeimer (2001)
10.1016/0169-409X(95)00017-2
Microspheres and nanoparticles used in ocular delivery systems
A. Zimmer (1995)
Hydrogel nanocomposites for ophthalmic applications
N Ravi (2012)
10.1016/J.EXER.2005.09.003
Treatment of experimental autoimmune uveoretinitis with poly(lactic acid) nanoparticles encapsulating betamethasone phosphate.
T. Sakai (2006)
10.1023/A:1018977130559
Design of New Formulations for Topical Ocular Administration: Polymeric Nanocapsules Containing Metipranolol
C. Losa (2004)
10.1023/A:1023290514575
Influence of Preparation Conditions on Acyclovir-Loaded Poly-d,l-Lactic Acid Nanospheres and Effect of PEG Coating on Ocular Drug Bioavailability
C. Giannavola (2004)
American Pharmacists Association (2006) Handbook of pharmaceutical excipients
RC Rowe (2006)
10.3109/10717549609031179
Ocular disposition of nanoencapsulated acyclovir and ganciclovir via intravitreal injection in rabbit's eye
M. El-Samaligy (1996)
10.22377/AJP.V4I4.290
Acyclovir-loaded chitosan nanoparticles for ocular delivery
N. RajendranN (2010)
10.1016/0378-5173(93)90304-X
Surface modification of i.v. injectable biodegradable nanoparticles with poloxamer polymers and poloxamine 908
R. Mueller (1993)
10.1016/J.PROGPOLYMSCI.2006.08.004
From controlled ring-opening polymerization to biodegradable aliphatic polyester: Especially poly(β-malic acid) derivatives
O. Coulembier (2006)
10.1248/CPB.59.272
Chitosan nanoparticles of 5-fluorouracil for ophthalmic delivery: characterization, in-vitro and in-vivo study.
R. C. Nagarwal (2011)
10.1021/mp900279c
Mucoadhesive nanoparticles as carrier systems for prolonged ocular delivery of gatifloxacin/prednisolone bitherapy.
H. K. Ibrahim (2010)
10.2147/IJN.S28481
Role of hydroxypropyl-β-cyclodextrin on freeze-dried and gamma-irradiated PLGA and PLGA–PEG diblock copolymer nanospheres for ophthalmic flurbiprofen delivery
E. Vega (2012)
10.1016/j.jconrel.2009.05.033
New formulation of vasoactive intestinal peptide using liposomes in hyaluronic acid gel for uveitis.
Laure Lajavardi (2009)
10.1016/J.JCONREL.2007.06.009
Gold nanoparticles enable selective light-induced contents release from liposomes.
Lauri Paasonen (2007)
10.1080/10611860701453125
Piroxicam nanoparticles for ocular delivery: Physicochemical characterization and implementation in endotoxin-induced uveitis
Khosro Adibkia (2007)
10.3390/POLYM3031377
Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier.
Hirenkumar K. Makadia (2011)
10.1208/s12249-011-9675-1
Brimonidine Tartrate–Eudragit Long-Acting Nanoparticles: Formulation, Optimization, In Vitro and In Vivo Evaluation
Prakash Bhagav (2011)
10.1097/ICU.0b013e3281108000
Drug delivery methods for posterior segment disease
Jason Hsu (2007)
10.1016/1350-9462(96)00014-6
Delivery of drugs to the eye by topical application
Hitoshi Sasaki (1996)
10.1211/jpp.57.12.0005
Size‐dependent disposition of nanoparticles and microparticles following subconjunctival administration
A. Amrite (2005)
10.1179/030801800679206
Drug delivery systems
S. Davis (1983)
10.1016/J.EJPB.2007.09.009
Chitosan-sodium alginate nanoparticles as submicroscopic reservoirs for ocular delivery: formulation, optimisation and in vitro characterisation.
S. Motwani (2008)
10.1016/S0168-3659(97)00106-5
Influence of experimental parameters on the characteristics of poly(lactic acid) nanoparticles prepared by a double emulsion method.
M. Zambaux (1998)
Use of biologic agents in the treatment of uveitis: these potent new agents may help some patients who are refractory to more traditional immunosuppressive therapies
S Pasadhika (2010)
10.1371/journal.pone.0000038
Efficient Non-Viral Ocular Gene Transfer with Compacted DNA Nanoparticles
R. Farjo (2006)
10.1016/0378-5173(87)90050-0
A γ-scintigraphic evaluation of microparticulate ophthalmic delivery systems: liposomes and nanoparticles
P. Fitzgerald (1987)
10.1016/S1359-0286(02)00117-1
Biodegradable nanoparticles for drug delivery and targeting
M. Hans (2002)
10.1016/0378-5173(94)90243-7
Hydrocortisone delivery to healthy and inflamed eyes using a micellar polysorbate 80 solution or albumin nanoparticles
A. Zimmer (1994)
10.1016/J.EXER.2007.10.004
High-efficacy site-directed drug delivery system using sialyl-Lewis X conjugated liposome.
N. Hashida (2008)
10.1016/0960-9822(92)90185-D
Leukocyte—endothelial cell interactions
R. McEver (1992)
Intracellular trafficking of hyaluronic acid-chitosan oligomer-based nanoparticles in cultured human ocular surface cells
Laura Contreras-Ruiz (2011)
10.1016/j.preteyeres.2004.02.003
Drug delivery systems for vitreoretinal diseases
T. Yasukawa (2004)
Preparation and characterization of eudragit retard nanosuspensions for the ocular delivery of cloricromene.
R. Pignatello (2006)
A clinical trial with Piloplex--a new long-acting pilocarpine compound: preliminary report.
U. Ticho (1979)
10.1016/j.nano.2008.07.003
Diclofenac-loaded biopolymeric nanosuspensions for ophthalmic application.
Sagar M. Agnihotri (2009)
10.1016/0378-5173(95)00142-6
Influence of the preparation conditions on poly(ethylcyanoacrylate) nanocapsule formation
G. Puglisi (1995)
10.2217/nnm.12.175
Doxorubicin-loaded MePEG-PCL nanoparticles for prevention of posterior capsular opacification.
R. Guha (2013)
Chitosan nanoparticles for controlled delivery of brimonidine tartrate to the ocular membrane.
K. Singh (2011)
10.3109/02652048909019905
Manufacture of polyalkylcyanoacrylate nanoparticles with pilocarpine and timolol by micelle polymerization: factors influencing particle formation.
T. Harmia-Pulkkinen (1989)
10.1016/J.JCONREL.2004.11.023
In vitro and in vivo activities of verteporfin-loaded nanoparticles.
Y. Konan-Kouakou (2005)
10.1167/iovs.13-11825
Mobility experiments with microrobots for minimally invasive intraocular surgery.
F. Ullrich (2013)
10.1016/J.EURPOLYMJ.2004.09.015
Characterization and release of triptolide-loaded poly (D, L-lactic acid) nanoparticles
Mingxing Liu (2005)
10.1016/0378-5173(85)90007-9
Ocular disposition of poly-hexyl-2-cyano[3-14C]acrylate nanoparticles in the albino rabbit
R. Wood (1985)
10.1016/S0142-9612(01)00284-8
Ocular disposition and tolerance of ganciclovir-loaded albumin nanoparticles after intravitreal injection in rats.
M. Merodio (2002)
10.1002/eji.200425022
Intraocular injection of tamoxifen‐loaded nanoparticles: a new treatment of experimental autoimmune uveoretinitis
Y. de Kozak (2004)
10.2174/1567210204970992018
Development and Evaluation of Novel Polymeric Nanoparticles of Brimonidine Tartrate.
K. Singh (2010)
10.1016/j.jconrel.2010.11.029
Suppression of phagocytic cells in retinal disorders using amphiphilic poly(γ-glutamic acid) nanoparticles containing dexamethasone.
Morin Ryu (2011)
10.1167/iovs.10-6229
Anti-inflammatory and antiangiogenic effects of nanoparticle-mediated delivery of a natural angiogenic inhibitor.
J. Jin (2011)
10.1016/j.jconrel.2008.12.018
Polymeric nanoparticulate system: a potential approach for ocular drug delivery.
R. C. Nagarwal (2009)
Nanoparticles for gene delivery to retinal pigment epithelial cells.
R. Bejjani (2005)
10.1016/j.carbpol.2013.01.054
Evaluation of tropicamide-loaded tamarind seed xyloglucan nanoaggregates for ophthalmic delivery.
N. Dilbaghi (2013)
Current and future ophthalmic drug delivery systems
E. Amo (2008)
Gatifl oxacin nanoparticles for ophthalmic delivery. Nanotechnology
SK Motwani (2007)
10.1016/S0079-6700(02)00012-6
Properties of lactic acid based polymers and their correlation with composition
A. Södergård (2002)
Collagen – biomaterial for drug delivery 1
W. Frieß (1998)
10.1021/BP00011A004
Formation of Bioerodible Polymeric Microspheres and Microparticles by Rapid Expansion of Supercritical Solutions
J. Tom (1991)
10.1111/j.2042-7158.1991.tb03534.x
Improvement of Ocular Penetration of Amikacin Sulphate by Association to Poly(butylcyanoacrylate) Nanoparticles
C. Losa (1991)
10.1016/J.IJPHARM.2006.10.004
Phase transition water-in-oil microemulsions as ocular drug delivery systems: in vitro and in vivo evaluation.
Judy Chan (2007)
10.1155/2012/203819
Use of Biologic Agents in Ocular Manifestations of Rheumatic Disease
C. Kraus (2012)
10.1016/j.exer.2013.04.007
Biodegradable nanoparticles for controlled subconjunctival delivery of latanoprost acid: in vitro and in vivo evaluation. Preliminary results.
Athanassios Giarmoukakis (2013)
10.1016/S0378-5173(01)00760-8
Chitosan nanoparticles: a new vehicle for the improvement of the delivery of drugs to the ocular surface. Application to cyclosporin A.
A. M. de Campos (2001)
10.1038/gt.2008.16
Bioadhesive hyaluronan–chitosan nanoparticles can transport genes across the ocular mucosa and transfect ocular tissue
M. Fuente (2008)
10.2147/IJN.S6428
Pharmacokinetics and tolerance study of intravitreal injection of dexamethasone-loaded nanoparticles in rabbits
L. Zhang (2009)
10.1016/J.IJPHARM.2006.06.036
Formation of self-organized nanoparticles by lecithin/chitosan ionic interaction.
F. Sonvico (2006)
10.1016/J.NANO.2005.12.003
Nanoencapsulation I. Methods for preparation of drug-loaded polymeric nanoparticles.
C. Reis (2006)
Nanoparticle characterization : a comprehensive physicochemical approach
B. Magenheim (1991)
10.1016/S0378-5173(00)00593-7
Sterilization of poly(dimethylamino) ethyl methacrylate-based gene transfer complexes.
G. Bos (2000)
10.1166/JBN.2010.1168
Chitosan coated PLA nanoparticles for ophthalmic delivery: characterization, in-vitro and in-vivo study in rabbit eye.
R. C. Nagarwal (2010)
10.1002/mabi.201100005
Hybrid nanoparticle design based on cationized gelatin and the polyanions dextran sulfate and chondroitin sulfate for ocular gene therapy.
G. K. Zorzi (2011)
10.1016/0378-5173(90)90248-3
Antiglaucomatous activity of betaxolol chlorhydrate sorbed onto different isobutylcyanoacrylate nanoparticle preparations
L. Marchal-Heussler (1990)
Clathrin and caveolin-1 expression in primary pigmented rabbit conjunctival epithelial cells: role in PLGA nanoparticle endocytosis.
Mohamed G. Qaddoumi (2003)
10.1016/S0928-0987(00)00169-X
Ganciclovir-loaded albumin nanoparticles: characterization and in vitro release properties.
M. Merodio (2001)
10.1016/S0928-0987(02)00057-X
Eudragit RS100 nanosuspensions for the ophthalmic controlled delivery of ibuprofen.
R. Pignatello (2002)
10.1167/IOVS.02-0791
Subconjunctival nano- and microparticles sustain retinal delivery of budesonide, a corticosteroid capable of inhibiting VEGF expression.
U. Kompella (2003)
10.3109/02652049109021873
Studies on the transport pathway of PBCA nanoparticles in ocular tissues.
A. Zimmer (1991)
10.1016/j.nano.2009.02.003
Nanomedicines for ocular NSAIDs: safety on drug delivery.
J. Araújo (2009)
10.1159/000065608
Enhanced Ocular Anti-Inflammatory Activity of Ibuprofen Carried by an Eudragit RS100® Nanoparticle Suspension
C. Bucolo (2002)
10.1002/(SICI)1097-4628(19970103)63:1<125::AID-APP13>3.0.CO;2-4
Novel hydrophilic chitosan‐polyethylene oxide nanoparticles as protein carriers
P. Calvo (1997)
10.1089/jop.2011.0155
Differential expression of folate receptor-alpha, sodium-dependent multivitamin transporter, and amino acid transporter (B (0, +)) in human retinoblastoma (Y-79) and retinal pigment epithelial (ARPE-19) cell lines.
J. Jwala (2012)
10.2478/folmed-2013-0009
Indomethacin Nanoparticles for Applications in Liquid Ocular Formulations / Наночастицы С Индометацином Для Применения В Жидких Лекарственных Формах Для Глаз
V. Andonova (2013)
10.2174/1567201811310050001
Betaxolol hydrochloride loaded chitosan nanoparticles for ocular delivery and their anti-glaucoma efficacy.
Kunal Jain (2013)
10.1155/2013/562727
Development of Dorzolamide Loaded 6-O-Carboxymethyl Chitosan Nanoparticles for Open Angle Glaucoma
U. Shinde (2013)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar